C4 Therapeutics fills out C-Suite with CEO appointment
pharmafile | May 10, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | C4 Therapeutics, biotech, drugs, pharma, pharmaceutical
C4 Therapeutics has been slowly expanding since its creation in early 2016 out of the prestigious Dana-Farber Cancer Institute. Andrew Phillips has been working at the company since its inception as Chief Scientific Officer but has now been given the role of Chief Executive Officer.
Phillips had previously been working as President alongside his CSO position before the elevation of his duties to CEO. Alongside this appointment came the promotion of Stewart Fisher to fill the vacant position left by Phillips.
It also means the C-suite of the small, Boston-based biotech, is now complete, with Co-founder and Executive Chairman, Marc Cohen, and Ron Kaiser, as Chief Financial Officer, rounding out the top level team.
“Andy has played a key role in C4T’s growth and has helped define who we are today as a company,” said Marc Cohen, Co-founder and Executive Chairman of C4T. “In addition to being a world-class scientist, Andy has provided exemplary leadership in recruiting a phenomenal management team, developing a robust internal pipeline of projects, and nurturing our strategic alliances with Roche and Calico. I look forward to working with Andy as CEO as we continue to build C4T’s targeted protein degradation platform and advance degraders into the clinic to address areas of high unmet medical need.”
Phillips began as a professor at the University of Colorado at Boulder, before moving onto teach at Yale for close to five years and then moving to be Senior Director at the Broad Institute.
The biotech’s area of focus is use its platform to discover new therapeutic candidates that address a range of diseases, including cancer, through targeted protein degradation. In particular, it will focusing on developing therapeutics to degrade BRD4, a reader protein that certain cancer cells depend on for function.
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …
